Distribution of human papillomavirus genotypes among cervical intraepithelial neoplasia and invasive cancers in Macao.
Macao is a densely populated city situated in East Asia where a relatively high prevalence of human papillomavirus (HPV) types 52 and 58 has been reported in women with invasive cervical cancer. To provide data for a population-specific estimation on the impact of HPV vaccines, paraffin-embedded tissues collected from women with invasive cervical cancer or cervical intrapeitheilal neoplasia grade 2 or 3 confirmed histologically were examined for HPV using the INNO-LiPa kit. Of the 35 HPV-positive patients with invasive cancer, one HPV type was detected in 68.6%, and 31.4% were co-infected with more than one HPV type. Overall, HPV 16, HPV 18, HPV 52, and HPV 54 were the most common types found respectively in 57.1%, 17%, 11.4%, and 8.5% of patients with invasive cervical cancer. Among the 59 HPV-positive patients with cervical intraepithelial neoplasia grade 2/3, 55.9% hardbored one HPV type, and 44.1% had co-infections. The common HPV types found included HPV 16 (52.5%), HPV 52 (23.7%), HPV 58 (18.7%), and HPV 33 (17%). Although HPV 11 (a low-risk type) was also found commonly in invasive cervical cancers (14.3%) and cervical intraepithelial neoplasia grade 2/3 (15.3%), the fact that they all existed as co-infections with another high-risk type suggested HPV 11 was not the cause of the lesion. The current vaccines targeting HPV 16/18 are expected to cover 62.9-74.3% of invasive cervical cancers and 32.2-55.9% of cervical intraepithelial neoplasia 2/3 in Macao. Widespread HPV vaccination is expected to reduce substantially the disease burden associated with cervical neoplasia in Macao.
Hlaing
Thazin
T
Department of Anatomic Pathology, Centro Hospitalar Conde de Sao Januario, Macao Special Administrative Region, China.
Yip
Yuk-Ching
YC
Ngai
Karry L K
KL
Vong
Heong-Ting
HT
Wong
Sio-In
SI
Ho
Wendy C S
WC
Batalha
Sellma L S C
SL
Chan
Paul K S
PK
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D006801:Humans; D008256:Macau / Q000453:epidemiology; D008875:Middle Aged; D017720:Molecular Epidemiology; D027383:Papillomaviridae / Q000145:classification* / Q000235:genetics / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000821:virology*; D053918:Papillomavirus Vaccines / Q000145:classification; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000821:virology*; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology* / Q000821:virology*
D004279:DNA, Viral; D053918:Papillomavirus Vaccines